Early Trial Data Puts Aclaris’ ATI-052 on Fast Track Toward Bigger Bets
WAYNE, PA — Aclaris Therapeutics Inc. (NASDAQ: ACRS) said positive interim data from its first-in-human study of ATI-052 are accelerating the experimental drug’s push toward later-stage trials, signaling what the …
Early Trial Data Puts Aclaris’ ATI-052 on Fast Track Toward Bigger Bets Read More